2007
On the Need to Compensate for Edema-Induced Dose Reductions in Preplanned 131Cs Prostate Brachytherapy
Chen ZJ, Deng J, Roberts K, Nath R. On the Need to Compensate for Edema-Induced Dose Reductions in Preplanned 131Cs Prostate Brachytherapy. International Journal Of Radiation Oncology • Biology • Physics 2007, 70: 303-310. PMID: 17980500, PMCID: PMC2289996, DOI: 10.1016/j.ijrobp.2007.09.007.Peer-Reviewed Original ResearchConceptsDose reductionProstate brachytherapyDose compensationLarge edemaBiochemical recurrence-free survivalRecurrence-free survivalSignificant dose reductionEffects of edemaSublethal damage repairAdditional irradiationPrescription doseProstate cancerIndividual patientsEdemaEdema evolutionPrescribed doseProstate edemaEffective doseRadiobiologic effectsBrachytherapyDoseProstate implantsDose responseImplants
2004
Iodine 125 Versus Palladium 103 Implants for Prostate Cancer
Peschel RE, Colberg JW, Chen Z, Nath R, Wilson LD. Iodine 125 Versus Palladium 103 Implants for Prostate Cancer. The Cancer Journal 2004, 10: 170-174. PMID: 15285926, DOI: 10.1097/00130404-200405000-00006.Peer-Reviewed Original ResearchConceptsExternal beam radiation therapyMinimum tumor doseDisease-free survival ratesComplication rateTumor doseProstate cancerRadiation therapyClinical outcomesPrognostic groupsBiochemical disease-free survival ratesSurvival rateBiochemical disease-free survivalDisease-free survivalHigh complication ratePoor prognostic groupProstate-specific antigenHormonal therapyT stageGleason scoreSingle institutionTransperineal implantationFavorable groupGrade 3Treatment groupsPatients
1998
Correlation of medical dosimetry quality indicators to the local tumor control in patients with prostate cancer treated with iodine‐125 interstitial implants
Nath R, Roberts K, Ng M, Peschel R, Chen Z. Correlation of medical dosimetry quality indicators to the local tumor control in patients with prostate cancer treated with iodine‐125 interstitial implants. Medical Physics 1998, 25: 2293-2307. PMID: 9874821, DOI: 10.1118/1.598440.Peer-Reviewed Original ResearchConceptsSurvival rateProstate cancerInterstitial implantsLocal recurrence-free survival rateRecurrence-free survival ratesLocal control rateLocal tumor controlExcellent clinical resultsProstate cancer patientsUnfavorable groupClinical efficacyCancer patientsControl rateTumor controlClinical resultsFavorable groupDose coveragePatientsDosimetric parametersDosimetry parametersIsodose surfaceSignificant differencesVirginia studyUnfavorable parametersCancer